Triple-negative breast cancer: treatment challenges and solutions

References

• TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
   PubMed Web of Science ®Google Scholar
• PerouCMSørlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• SørlieTPerouCMTibshiraniRGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProc Natl Acad Sci U S A20019819108691087411553815
   PubMed Web of Science ®Google Scholar
• GoldhirschAIngleJNGelberRDCoatesASThürlimannBSennHJThresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009Ann Oncol20092081319132919535820
   PubMed Web of Science ®Google Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerArch Pathol Lab Med20071311184319548375
   PubMed Web of Science ®Google Scholar
• DentRTrudeauMPritchardKITriple-negative breast cancer: clinical features and patterns of recurrenceClin Cancer Res20071315 Pt 14429443417671126
   PubMed Web of Science ®Google Scholar
• IrvinWJJrCareyLAWhat is triple-negative breast cancer?Eur J Cancer200844182799280519008097
   PubMed Web of Science ®Google Scholar
• LinNUClausESohlJRazzakARArnaoutAWinerEPSites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastasesCancer2008113102638264518833576
   PubMed Web of Science ®Google Scholar
• NielsenTOHsuFDJensenKImmunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinomaClin Cancer Res200410165367537415328174
   PubMed Web of Science ®Google Scholar
• RakhaEAReis-FilhoJSEllisIOBasal-like breast cancer: a critical reviewJ Clin Oncol200826152568258118487574
   PubMed Web of Science ®Google Scholar
• Reis-FilhoJSTuttANTriple negative tumours: a critical reviewHistopathology200852110811818171422
   PubMed Web of Science ®Google Scholar
• FoulkesWDSmithIEReis-FilhoJSTriple-negative breast cancerN Engl J Med2010363201938194821067385
   PubMed Web of Science ®Google Scholar
• BauerKRBrownMCressRDPariseCACaggianoVDescriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer RegistryCancer200710991721172817387718
   PubMed Web of Science ®Google Scholar
• CareyLAPerouCMLivasyCARace, breast cancer subtypes, and survival in the Carolina Breast Cancer StudyJAMA2006295212492250216757721
   PubMed Web of Science ®Google Scholar
• EiermannWBerghJCardosoFTriple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial designBreast2012211202621983489
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAMTimmsKMLiuSIncidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancerClin Cancer Res20111751082108921233401
   PubMed Web of Science ®Google Scholar
• DalyMBPilarskiRAxilbundJEGenetic/familial high-risk assessment: breast and ovarian, Version 2.2015J Natl Compr Canc Netw201614215316226850485
   PubMed Web of Science ®Google Scholar
• LiedtkeCMazouniCHessKRResponse to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancerJ Clin Oncol20082681275128118250347
   PubMed Web of Science ®Google Scholar
• CareyLADeesECSawyerLThe triple negative paradox: primary tumor chemosensitivity of breast cancer subtypesClin Cancer Res20071382329233417438091
   PubMed Web of Science ®Google Scholar
• LehmannBDPietenpolJAIdentification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypesJ Pathol2014232214215024114677
   PubMed Web of Science ®Google Scholar
• MontagnaEMaisonneuvePRotmenszNHeterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcomeClin Breast Cancer2013131313923098574
   PubMed Web of Science ®Google Scholar
• KandilDKhanATriple negative breast carcinoma: the good, the bad and the uglyDiagn Histopathol (Oxf)2012185210216
   Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
   PubMed Web of Science ®Google Scholar
• ShahSPRothAGoyaRThe clonal and mutational evolution spectrum of primary triple-negative breast cancersNature2012486740339539922495314
   PubMed Web of Science ®Google Scholar
• LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
   PubMed Web of Science ®Google Scholar
• HerschkowitzJISiminKWeigmanVJIdentification of conserved gene expression features between murine mammary carcinoma models and human breast tumorsGenome Biol200785R7617493263
   PubMed Web of Science ®Google Scholar
• PratAParkerJSKarginovaOPhenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Res2010125R6820813035
   PubMed Web of Science ®Google Scholar
• BursteinMDTsimelzonAPoageGMComprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancerClin Cancer Res20152171688169825208879
   PubMed Web of Science ®Google Scholar
• MasudaHBaggerlyKAWangYDifferential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypesClin Cancer Res201319195533554023948975
   PubMed Web of Science ®Google Scholar
• HoeijmakersJHGenome maintenance mechanisms for preventing cancerNature2001411683536637411357144
   PubMed Web of Science ®Google Scholar
• HoeijmakersJHBootsmaDDNA repair: incisions for excisionNature199437164996546557935809
   PubMed Web of Science ®Google Scholar
• VenkitaramanARCancer susceptibility and the functions of BRCA1 and BRCA2Cell2002108217118211832208
   PubMed Web of Science ®Google Scholar
• Metzger-FilhoOTuttAde AzambujaEDissecting the heterogeneity of triple-negative breast cancerJ Clin Oncol201230151879188722454417
   PubMed Web of Science ®Google Scholar
• TurnerNCReis-FilhoJSBasal-like breast cancer and the BRCA1 phenotypeOncogene200625435846585316998499
   PubMed Web of Science ®Google Scholar
• TurnerNTuttAAshworthAHallmarks of ‘BRCAness’ in sporadic cancersNat Rev Cancer200441081481915510162
   PubMed Web of Science ®Google Scholar
• LipsEHMulderLOonkATriple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriersBr J Cancer2013108102172217723558900
   PubMed Web of Science ®Google Scholar
• EstellerMEpigenetics in cancerN Engl J Med2008358111148115918337604
   PubMed Web of Science ®Google Scholar
• EstellerMSilvaJMDominguezGPromoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumorsJ Natl Cancer Inst200092756456910749912
   PubMedGoogle Scholar
• McLornanDPListAMuftiGJApplying synthetic lethality for the selective targeting of cancerN Engl J Med2014371181725173525354106
   PubMed Web of Science ®Google Scholar
• SchoutenPCLinnSCChallenges in the use of DNA repair deficiency as a biomarker in breast cancerJ Clin Oncol201533171867186925918281
   PubMed Web of Science ®Google Scholar
• WatkinsJAIrshadSGrigoriadisATuttANGenomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersBreast Cancer Res201416321125093514
   PubMed Web of Science ®Google Scholar
• TimmsKMAbkevichVHughesEAssociation of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypesBreast Cancer Res201416647525475740
   PubMed Web of Science ®Google Scholar
• SledgeGWJrRothBJCisplatin in the management of breast cancerSemin Oncol1989164 Suppl 61101152669132
   PubMed Web of Science ®Google Scholar
• SirohiBArnedosMPopatSPlatinum-based chemotherapy in triple-negative breast cancerAnn Oncol200819111847185218567607
   PubMed Web of Science ®Google Scholar
• StaudacherLCottuPHDiérasVPlatinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experienceAnn Oncol201122484885620924076
   PubMed Web of Science ®Google Scholar
• IsakoffSJMayerELHeLTBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancerJ Clin Oncol201533171902190925847936
   PubMed Web of Science ®Google Scholar
• TuttAEllisPKilburnLThe TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer [abstract]2014 Available from: http://www.abstracts2view.com/sabcs14/view.php?nu=SABCS13L_789Accessed January 1, 2016
   Google Scholar
• CareyLADeesECSawyerLThe triple negative paradox: primary tumor chemosensitivity of breast cancer subtypesClin Cancer Res20071382329233417438091
   PubMed Web of Science ®Google Scholar
• CortazarPZhangLUntchMPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384993816417224529560
   PubMed Web of Science ®Google Scholar
• ByrskiTGronwaldJHuzarskiTPathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapyJ Clin Oncol201028337537920008645
   PubMed Web of Science ®Google Scholar
• ZhangPYinYXuBCarboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for triple-negative breast cancer – a phase II clinical trialCancer Res201373P3-14-07
   Web of Science ®Google Scholar
• von MinckwitzGSchneeweissALoiblSNeoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialLancet201415774775624794243
   PubMed Web of Science ®Google Scholar
• SikovWMBerryDAPerouCMImpact of the addition of carboplatin and-or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin an cyclophosphamide on pathologic complete response rates in stages II to III triple negative breast cancer: CALGB 40603 (Alliance)J Clin Oncol2015331132125092775
   PubMed Web of Science ®Google Scholar
• AlbaEChaconJILluchAA randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting: results from the GEICAM/2006-03, multicenter studyBreast Cancer Res Treat2012136248749323053638
   PubMed Web of Science ®Google Scholar
• No authors listedPositive results for drug combo in I-SPY 2 trialCancer Discov201442OF2
   Google Scholar
• von MinckwitzGLoiblSSchneeweissAEarly survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)Cancer Res201676S2S4
   Web of Science ®Google Scholar
• German Breast GroupA phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM[Cb]) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto)2016 Available from: https://clinicaltrials.gov/ct2/show/NCT02125344Accessed December 24, 2015
   Google Scholar
• CoatesASWinerEPGoldhirschATailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Ann Oncol20152681533154625939896
   PubMed Web of Science ®Google Scholar
• FaschingPALoiblSEidtmannHBRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study2015 Available from: http://www.abstracts2view.com/sabcs15/view.php?nu=SABCS15L_822&terms=Accessed January 1, 2016
   Google Scholar
• FongPCBossDSYapTAInhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersN Engl J Med2009361212313419553641
   PubMed Web of Science ®Google Scholar
• TuttARobsonMGarberJEOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialLancet2010376973723524420609467
   PubMed Web of Science ®Google Scholar
• KaufmanBShapira-FrommerRSchmutzlerRKOlaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationJ Clin Oncol201533324425025366685
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• SonnenblickAde AzambujaEAzimHAJrPiccartMAn update on PARP inhibitors – moving to the adjuvant settingNat Rev Clin Oncol2015121274125286972
   PubMed Web of Science ®Google Scholar
• NiemeierLADabbsDJBeriwalSStriebelJMBhargavaRAndrogen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiationMod Pathol201023220521219898421
   PubMed Web of Science ®Google Scholar
• BartonVND’AmatoNCGordonMAChristensonJLEliasARicherJKAndrogen receptor biology in triple negative breast cancer: a case for classification as AR+ or quadruple negative diseaseHorm Cancer201565–620621326201402
   PubMed Web of Science ®Google Scholar
• Proverbs-SinghTFeldmanJLMorrisMJAutioKATrainaTATargeting the androgen receptor in prostate and breast cancer: several new agents in developmentEndocr Relat Cancer2015223R87R10625722318
   PubMed Web of Science ®Google Scholar
• FarmerPBonnefoiHBecetteVIdentification of molecular apocrine breast tumours by microarray analysisOncogene200524294660467115897907
   PubMed Web of Science ®Google Scholar
• DoaneASDansoMLalPAn estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgenOncogene200625283994400816491124
   PubMed Web of Science ®Google Scholar
• GucalpATolaneySIsakoffSJPhase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancerClin Cancer Res201319195505551223965901
   PubMed Web of Science ®Google Scholar
• TrainaTAO’ShaughnessyJNandaRAbstract P5-19-09: preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)Cancer Res201575P5-19-09
   Web of Science ®Google Scholar
• TrainaTAMillerKYardleyDAResults from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)J Clin Oncol201533 Suppl1003
   Web of Science ®Google Scholar
• Arce-SalinasCRiesco-MartinezMCHannaWBedardPHWarnerEComplete response of metastatic androgen receptor-positive breast cancer to bicalutamide: case report and review of the literatureJ Clin Oncol2016344e21e2424888812
   PubMed Web of Science ®Google Scholar
• AnestisAKaramouzisMVDalagiorgouGPapavassiliouAGIs androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?Cancer Treat Rev201541654755325944485
   PubMed Web of Science ®Google Scholar
• LoiSTumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacyOncoimmunology201327e2472024073365
   PubMed Web of Science ®Google Scholar
• LoiSMichielsSSalgadoRTumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialAnn Oncol20142581544155024608200
   PubMed Web of Science ®Google Scholar
• IbrahimEMAl-FoheidiMEAl-MansourMMKazkazGAThe prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysisBreast Cancer Res Treat2014148346747625361613
   PubMed Web of Science ®Google Scholar
• AdamsSGrayRJDemariaSPrognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199J Clin Oncol201432272959296625071121
   PubMed Web of Science ®Google Scholar
• LoiSSirtaineNPietteFPrognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98J Clin Oncol201331786086723341518
   PubMed Web of Science ®Google Scholar
• OnoMTsudaHShimizuCTumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancerBreast Cancer Res Treat2012132379380521562709
   PubMed Web of Science ®Google Scholar
• DenkertCLoiblSNoskeATumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancerJ Clin Oncol201028110511319917869
   PubMed Web of Science ®Google Scholar
• DenkertCvonMGBraseJCTumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancersJ Clin Oncol201533998399125534375
   PubMed Web of Science ®Google Scholar
• SmidMHoesMSieuwertsAMPatterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypesBreast Cancer Res Treat20111281233020632083
   PubMed Web of Science ®Google Scholar
• PostowMACallahanMKWolchokJDImmune checkpoint blockade in cancer therapyJ Clin Oncol201533171974198225605845
   PubMed Web of Science ®Google Scholar
• HometMBRibasAAnti-programmed cell death protein-1/ligand-1 therapy in different cancersBr J Cancer201511291421142725856776
   PubMed Web of Science ®Google Scholar
• GatalicaZSnyderCManeyTProgrammed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer typeCancer Epidemiol Biomarkers Prev201423122965297025392179
   PubMed Web of Science ®Google Scholar
• MittendorfEAPhilipsAVMeric-BernstamFPD-L1 expression in triple-negative breast cancerCancer Immunol Res20142436137024764583
   PubMed Web of Science ®Google Scholar
• NandaRChowLQDeesECAbstract S1-09: a phase IB study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancerCancer Res201575S1S9
   Web of Science ®Google Scholar
• EmensLABraitehFSCassierPInhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancerCancer Res201575PD1PD6
   Web of Science ®Google Scholar
• DirixLYTakacsINikolinakosPAvelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase IB JAVELIN solid tumor trialCancer Res201676S1S4
   Web of Science ®Google Scholar
• TungNMWinerEPTumor-infiltrating lymphocytes and response to platinum in triple-negative breast cancerJ Clin Oncol201533996997125559817
   PubMed Web of Science ®Google Scholar
• Cimino-MathewsAFooteJBEmensLAImmune targeting in breast cancerOncology (Williston Park)201529537538525979549
   PubMed Web of Science ®Google Scholar
• CameronDBrownJDentRAdjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trialLancet Oncol2013141093394223932548
   PubMed Web of Science ®Google Scholar
• TengYHTanWJThikeAAMutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapyBreast Cancer Res2011132R3521457545
   PubMed Web of Science ®Google Scholar
• MasudaHZhangDBartholomeuszCDoiharaHHortobagyiGNUenoNTRole of epidermal growth factor receptor in breast cancerBreast Cancer Res Treat2012136233134523073759
   PubMed Web of Science ®Google Scholar
• CareyLARugoHSMarcomPKTBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancerJ Clin Oncol201230212615262322665533
   PubMed Web of Science ®Google Scholar
• TurnerNGroseRFibroblast growth factor signalling: from development to cancerNat Rev Cancer201010211612920094046
   PubMed Web of Science ®Google Scholar
• WescheJHaglundKHaugstenEMFibroblast growth factors and their receptors in cancerBiochem J2011437219921321711248
   PubMed Web of Science ®Google Scholar
• TurnerNLambrosMBHorlingsHMIntegrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene201029142013202320101236
   PubMed Web of Science ®Google Scholar
• Abu-KhalafMMMayerIALittenJBA phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with metastatic breast cancer with alterations in the FGF pathwayCancer Res201575OT1-1-13
   Web of Science ®Google Scholar
• ShuSKLinCYHeHSResponse and resistance to BET bromodomain inhibitors in triple-negative breast cancerNature2016529758641341726735014
   PubMed Web of Science ®Google Scholar